Sanofi Net Change in Property, Plant, and Equipment 2010-2025 | SNY
Sanofi annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2025. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- Sanofi net change in property, plant, and equipment for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Sanofi net change in property, plant, and equipment for the twelve months ending March 31, 2025 was $-3.254B, a 27.19% increase year-over-year.
- Sanofi annual net change in property, plant, and equipment for 2024 was $-1.876B, a 13.7% decline from 2023.
- Sanofi annual net change in property, plant, and equipment for 2023 was $-2.174B, a 189.44% increase from 2022.
- Sanofi annual net change in property, plant, and equipment for 2022 was $-0.751B, a 52.08% decline from 2021.
Sanofi Annual Net Change in Property, Plant, and Equipment
(Millions of US $) |
| 2024 |
$-1,876 |
| 2023 |
$-2,174 |
| 2022 |
$-751 |
| 2021 |
$-1,568 |
| 2020 |
$-1,366 |
| 2019 |
$-663 |
| 2018 |
$220 |
| 2017 |
$-1,606 |
| 2016 |
$-2,074 |
| 2015 |
$-2,844 |
| 2014 |
$-1,712 |
| 2013 |
$-1,314 |
| 2012 |
$-1,613 |
| 2011 |
$-1,982 |
| 2010 |
$-1,915 |
| 2009 |
$-2,371 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.587B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
